# US 2015/0147347 A1 · Novel immunotherapy against several tumors including gastrointestinal and gastric cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147347 A1
- Document ID: US20150147347A1
- Status: Published application
- Kind: A1
- Application number: 14/615,539
- Filed: 2015-02-06
- Published: 2015-05-28
- Earliest claimed: 2010-03-19
- Assignees: Immatics Biotechnologies GmbH
- Applicants: immatics biotechnologies GmbH
- Inventors: Jens FRITSCHE; Toni WEINSCHENK; Steffen WALTER; Peter LEWANDROWSKI; Harpreet SINGH
- Web page: https://patentgrep.com/patent/US20150147347A1

## CPC

- A61K 38/1709: {from mammals}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 38/4886: {Metalloendopeptidases (3.4.24), e.g. collagenase}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0011: {Cancer antigens}
- A61P 35/00: Antineoplastic agents
- C07K 7/06: having 5 to 11 amino acids
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- G01N 33/505: {involving T-cells}
- A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/585: {wherein the target is cancer}
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

## Claims

### Claim 1

A peptide comprising a sequence having at least 80% homology to a sequence that is selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 68, SEQ ID NO: 69 and SEQ ID NO: 70 or a variant thereof, wherein the peptide is capable of inducing T cells cross-reacting with said peptide, and wherein said peptide is not a full-length polypeptide.

### Claim 2 (depends on 1)

The peptide according to claim 1, wherein said peptide has an overall length of not more than 100 amino acids.

### Claim 3 (depends on 1)

The peptide according to claim 1 having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or -II.

### Claim 4 (depends on 1)

The peptide according to claim 1 wherein the peptide consists essentially of an amino acid sequence according to SEQ ID NO: 23, SEQ ID NO: 68, SEQ ID NO: 69 and SEQ ID NO: 70.

### Claim 5 (depends on 1)

The peptide according to claim 1, wherein the peptide is modified and/or includes non-peptide bonds.

### Claim 6 (depends on 1)

The peptide according to claim 1, wherein the peptide is a fusion protein comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii).

### Claim 7 (depends on 1)

A nucleic acid, encoding a peptide according to claim 1, provided that the peptide is not the full human protein.

### Claim 8 (depends on 7)

The nucleic acid according to claim 7 which is DNA, cDNA, PNA, CNA, RNA or combinations thereof.

### Claim 9 (depends on 7)

An expression vector capable of expressing a nucleic acid according to claim 7.

### Claim 10 (depends on 1)

A peptide according to claim 1 for use in medicine.

### Claim 11 (depends on 7)

A host cell comprising a nucleic acid according to claim 7.

### Claim 12 (depends on 11)

The host cell according to claim 11 that is an antigen presenting cell.

### Claim 13 (depends on 12)

The host cell according to claim 12, wherein the antigen presenting cell is a dentritic cell.

### Claim 14 (depends on 1)

A method of producing a peptide according to claim 1, the method comprising culturing a host cell comprising a nucleic acid encoding the peptide and isolating the peptide from the host cell or its culture medium.

### Claim 15 (depends on 1)

An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to claim 1.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the antigen is loaded onto class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell by contacting a sufficient amount of the antigen with an antigen-presenting cell.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the antigen-presenting cell comprises an expression vector capable of expressing said peptide.

### Claim 18 (depends on 15)

Activated cytotoxic T lymphocytes (CTL), produced by the method according to claim 15, which selectively recognise a cell which aberrantly expresses a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 68, SEQ ID NO: 69 and SEQ ID NO: 70.

### Claim 19 (depends on 15)

A method of killing target cells in a patient which target cells aberrantly express a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 68, SEQ ID NO: 69 and SEQ ID NO: 70, the method comprising administering to the patient an effective number of cytotoxic T lymphocytes (CTL) as defined in claim 15.

### Claim 20 (depends on 1)

A pharmaceutical composition comprising an entity selected from the group consisting of:
a) a peptide according to claim 1;
b) a nucleic acid encoding the peptide;
c) an expression vector capable of expressing the nucleic acid;
d) a host cell comprising the expression vector;
e) an activated cytotoxic T lymphocyte (CTL) produced by an in vitro method comprising contacting in vitro CTL with antigen loaded human class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is the peptide.

### Claim 21 (depends on 20)

The pharmaceutical composition according to claim 20, wherein the pharmaceutical composition is a vaccine.

### Claim 22 (depends on 20)

The pharmaceutical composition according to claim 20, wherein the pharmaceutical composition is active against cancer.

### Claim 23 (depends on 22)

The pharmaceutical composition according to claim 22, wherein said cancer cells are gastric cancer cells, gastrointestinal cancer cells, colorectal cancer cells, pancreatic cancer cells, lung cancer cells or renal cancer cells.

### Claim 24 (depends on 1)

The peptide of claim 1 comprising a sequence having at least 90% homology to a sequence selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 68, SEQ ID NO: 69 and SEQ ID NO: 70 or a variant thereof.

### Claim 25 (depends on 1)

The peptide of claim 1 comprising a sequence having at least 95% homology to a sequence selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 68, SEQ ID NO: 69 and SEQ ID NO: 70 or a variant thereof.

### Claim 26 (depends on 1)

The peptide of claim 1 comprising a sequence selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 68, SEQ ID NO: 69 and SEQ ID NO: 70.

### Claim 27 (depends on 1)

The peptide of claim 1 having an overall length of not more than 30 amino acids.

### Claim 28 (depends on 1)

The peptide of claim 1 having an overall length of not more than 14 amino acids.
